ALKBH5 and pulmonary fibrosis: Mitigation of these effects by Mito‐TEMPO underscores the potential for targeted interventions against 1‐nitropyrene induced pulmonary fibrosis through modulation of ALKBH5 SUMOylation.[123] In addition to impacting ALKBH5, SUMOylation also significantly influences the stability of FTO.